Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

ElixaMD vs Omnia TeleHealth

ElixaMD
Graded #251

Higher grade

vs+7.5
Omnia TeleHealth
Graded #418

Lower grade

The verdict

ElixaMD takes it — 63.7/100 to 56.2/100.

ElixaMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. ElixaMD is a doctor-guided online weight-loss telehealth offering compounded semaglutide injections from $179 the first month, with free shipping, no membership, no contract, and no insurance required.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueElixaMD +6
51
45
Dose & formulationElixaMD +12
52
40
Clinical oversightElixaMD +12
92
80
Labs & monitoringElixaMD +2
63
61
FulfillmentElixaMD +14
76
62
Contract termsOmnia TeleHealth +10
45
55
ElixaMD · left barOmnia TeleHealth · right bar

The numbers

MetricElixaMDOmnia TeleHealth
WeighScore63.7/10056.2/100
GradeCC
Scorecard rank#251#418
Semaglutide$179/mo (starting dose, first-month rate, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
ElixaMD

Graded #251 · C

Strengths

  • Compounded semaglutide from $179 first month with free shipping, no membership, no contract, and no insurance required
  • Genuinely all-inclusive: 1:1 physician guidance, free dietician visits and care coaching, 24/7 support, and an all-in-one patient portal
  • Names its compounding pharmacies (RedRock Pharmacy, Beaker Pharmacy) — more transparent than most compounded sellers
  • HSA/FSA eligible; full legal suite (Terms, Privacy, Privacy Practices, Refund, Medical Consent, California Bill of Rights)

Where it loses points

  • $179 is a first-month/intro price — ongoing monthly cost is higher (tiers to ~$249-$299)
  • Compounded semaglutide is not FDA-approved (the site discloses this) — not brand Wegovy or Ozempic
  • Appears to offer compounded semaglutide only — tirzepatide is not advertised
  • Displays a generic LegitScript Certified badge but no verifiable seal/listing; state-availability list not published
Omnia TeleHealth

Graded #418 · C

Strengths

  • LegitScript-certified; DNP-led by Blair Carmichael-Lober with 10+ years clinical experience
  • $69 flat consult fee — no insurance, no surprise bills; works with Belmar Pharma for compounded GLP-1
  • Both semaglutide and tirzepatide available; compounded options via Belmar at lower cost than brand
  • Weight loss visits include nutrition guidance, exercise recommendations, and behavioral coaching
  • Prescriptions sent to any pharmacy nationwide or coordinated through Belmar Pharma Solutions

Where it loses points

  • Only 17 states — specific states not publicly disclosed; must call (251) 220-8875 to confirm
  • Medication pricing is gated — not published on website; contact required for compounded GLP-1 cost
  • No labs mentioned or included — baseline bloodwork protocol not published on any page
  • Medication cost is a separate pharmacy bill; the $69 visit fee covers consult only
  • Smaller platform with limited public track record vs. larger national GLP-1 telehealth providers

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard